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Abstract
Introduction. The European Regional Office of the World Health Organization (WHO/
Europe) developed a strategic approach to stop the indigenous transmission of measles 
in its 53 Member States by 2015. This study describes the measles laboratory surveillance 
activity performed by the National Reference Laboratory for Measles and Rubella at the 
Italian National Institute of Health (Istituto Superiore di Sanità) during 2010.
Methods. Urine, oral fluid and capillary blood samples from 211 suspected measles 
cases arrived to the NRL from different regions of Italy for confirmation of the clinical 
diagnosis. Serological and/or molecular assays were performed; after molecular detection, 
positive samples were sequenced and genotyped.
Results and discussion. 85% (180/211) of the specimens were confirmed as measles 
cases and 139 of these were analyzed phylogenetically. The phylogenetic analysis revealed 
a co-circulation of D4 and D8 genotypes for the reviewed period.
INTroDuCTIoN 
Since 2001, the World Health Organization (WHO) 
has developed strategic plans to ensure global reduction 
in mortality from measles and make progress towards 
the interruption of its transmission. For the WHO 
European Region the interruption of indigenous 
transmission was initially expected by 2007 and the 
certification of the elimination by 2010 [1, 2]. In 
September 2010, the WHO Regional Committee for 
Europe set the displacement of the goals of elimination 
of measles and rubella and the reduction of cases of 
congenital rubella by 2015 [3]. The regional committee 
drew attention to the need to renew the political 
commitment, resources and actions to achieve these 
objectives. 
Globally, measles morbidity and mortality have 
been dramatically reduced since the implementation 
of enhanced vaccination strategies [4, 5], and the 
interruption of indigenous transmission of measles 
virus (MV) has been reported from several countries 
[6-8]. Furthermore, large outbreaks continue to occur 
in countries with high vaccination coverage after the 
importation of the virus from endemic regions [9-11].
In Italy, the goal of measles elimination was first fixed 
in 2003 with the National Plan for the Elimination of 
Measles and Congenital Rubella (PNEMoRc) with 
the final target to achieve and maintain the state of 
elimination at national level [12]. Measles vaccination 
is routinely delivered as a trivalent vaccine against 
measles, mumps, and rubella (MMR) offered free of 
charge, but the coverage levels are still below the target 
levels in most areas, and several outbreaks have been 
occurring since the beginning of 2010 in various Italian 
regions [13, 14].
In February 2011, Italy reiterated PNEMoRc, 
following the WHO Committee indications, to reach 
measles and rubella elimination by 2015. Then, the 
role of National Reference Laboratory (NRL) at the 
Italian National Institute of Health (Istituto Superiore 
di Sanità, Rome) in supporting cases ascertainment, 
confirming outbreaks/cases and determining MV 
genotypes was reconfirmed.
This article describes the laboratory surveillance 
activity performed by the Italian NRL during 2010.
METhoDS
A case of measles was defined as one that met the 
clinical case definition (clinical picture compatible with 
measles, i.e. a generalized rash lasting more than three 
days and a temperature >38.0 °C, with one or more of 
the following symptoms: cough, coryza, Koplik’s spots, 
conjunctivitis. 
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Urine, oral fluid specimens and dried blood spots 
collected within 10 days from the onset of the symptoms 
are the most suitable samples for the measles diagnosis, 
since they are used for both confirmation of the 
cases and molecular characterization. NRL provided 
sampling kits to the Italian local health authorities in 
order to collect these specimens.
Samples were collected in different Italian regions 
from 211 patients with clinical signs of measles, and 
sent to the NRL for confirmation of the diagnosis. 
Before collecting samples subjects, or their parents in 
case of children, had to sign the “informed consensus”.
NRL’s tests for confirmation included specific IgM 
antibodies detection in blood samples by enzyme-linked 
immunosorbent (ELISA) assay, molecular detection 
and genetic characterization of MV by PCR assay on 
urine and/or oral fluid samples. Urine and oral fluid 
specimens were collected as previous described [15, 
16], and the tests were performed under the indications 
of the National Plan of Elimination of Measles and 
Congenital Rubella (Manual for the laboratory diagnosis 
of measles and rubella infections). Three circles of 6 
mm ø, containing capillary blood, were punched-out 
from a dried blood spot and used for the ELISA assay 
(Siemens, Germany) [17]. 
Total RNA was extracted from urine sediment using 
RNEasy Mini Kit (Qiagen) and from oral fluid using 
QiAmp Viral RNA Mini Kit (Qiagen), according to 
the manufacturer’s instructions. Two rounds of PCR 
amplification were performed on a highly conserved 
region located on the N gene of the MV genome, 
as previous described [15, 18]. PCR products were 
sequenced by Macrogen DNA Sequencing Service 
(http://dna.macrogen.com) and sequence data 
about the 450 nucleotides that code for the carboxy-
terminal 150 amino acids of the nucleoprotein (N) 
were analysed phylogenetically. Phylogenetic analysis 
and tree reconstructions were performed with MEGA 
software version 6.06 [19]. Virus isolates and genotypes 
were named according to the new official WHO 
nomenclature [20, 21]. 
rESuLTS AND DISCuSSIoN
Clinical samples from a total of 211 patients with 
suspected measles infection arrived at NRL from 
different regions of Italy to confirm measles diagnosis 
by serological and molecular assays (Figure 1). Measles 
infection was confirmed for 180 of them.
The results obtained with different assays are shown 
in Table 1. Age distribution for 137 out 180 confirmed 
cases for which the data of birth was available is shown 
in (Figure 2). Urine samples were available for 164 
patients, for 62 also the blood sample was available. Of 
the latter, 49 were positive both in PCR and ELISA 
assays; 2 were PCR positive and IgM border line, 3 
patients were IgM positive but PCR negative. Samples 
from 8 patients were negative in both PCR and ELISA 
assays. Of the 102 patients for which only urine sample 
was available, 86 were positive.
Oral fluid samples from 36 patients were tested, and 
for 35 of these the blood sample was also available. 
Four-teen samples were positive in both PCR and 
Figure 1
Clinical samples tested for measles during 2010 grouped by type.
OF: oral fluid.
Figure 2  
Percentage of laboratory confirmed cases of measles by age group.
Age groups (years)
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IgM + IgM - BL Nonea Total
Urine
PCR + 49 0 2 86
164
PCR - 3 8 0 16
Oral
fluid
PCR + 14 1 0 1
36
PCR - 14 6 0 0
Bloodb 10 1 0 - 11
Total 211 211
a No blood or serum sample available; 
b No urine or oral fluid sample available.
Lab test
Vaccination status Positive Negative Total
1 dose 12 9 21
2 doses 0 4 4
Unvaccinated 95 9 104
Unspecified 70 12 82
Table 1
Results from molecular and serological tests performed on sus-
pected measles cases, during 2010
Table 2
Vaccination status of the patients with suspected measles infection
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ELISA assays; 1 was PCR positive and IgM negative, 14 
were IgM positive and PCR negative. Samples from 6 
patients were negative in both PCR and ELISA assays. 
For 1 patient only the oral fluid sample was available 
and it was PCR positive.
For 11 suspected cases only the blood sample was 
available, and the ELISA result was positive for 10 of 
these.
In summary, during 2010 NRL received samples from 
211 patients. The number of samples received and their 
distribution by type are shown in Figure 1. A total of 
62 suspected measles patients with both blood and 
urine samples were tested and 54 were confirmed. A 
percentage of 90.7% (49/54) was positive by both PCR 
and ELISA tests; 3.7% (2/54) was positive only in PCR 
and 5.6% (3/54) was positive only ELISA. Then, PCR 
on urine showed a samples positivity rate of 94.4%, and 
the total samples positivity rate in ELISA was 96.3%.
Samples from 35 suspected measles patients with 
both blood and saliva samples were tested in molecular 
and serological assays, and 29 were confirmed. Of these, 
a percentage of 48.3% (14/29) was positive in both PCR 
and ELISA tests; 3.4% (1/29) was positive in PCR only 
and 48.3% (14/29) was positive in ELISA only. Then, 
PCR on oral fluid showed a positivity rate of 51.7% and 
the total samples positivity rate in ELISA was 96.6%.
Despite this analysis involved an exiguous number of 
samples, these data might suggest that PCR performed 
on urine and ELISA performed on blood show a 
comparable yield, proving to be both more sensitive 
than PCR performed on oral fluid.
MV’s genome was found in 153 samples (urine or oral 
fluid). After viral detection, 139/153 were sequenced 
for viral characterization in order to attempt the current 
MV genotypes circulating in Italy. Phylogenetic analysis 
revealed a steady co-circulation of genotypes D4 and 
D8 during the reviewed period.
Vaccination status was available for 129 out of 211 
patients: 104 (80.6%) were unvaccinated, 21 (16.3%) 
received only one dose of measles-containing vaccine, 4 
(3.1%) were vaccinated with two doses (Table 2). Of the 
104 unvaccinated cases, 95 were positive and 9 were 
negative. Of the 21 cases vaccinated with a single dose 
12 were positive. All the 4 patients vaccinated with two 
doses were negative.
CoNCLuSIoNS
In September 2010, WHO European Region 
countries renewed their commitment to the elimination 
of indigenous transmission of measles by 2015. Thanks 
to continuous efforts by Member States to maintain 
high vaccination coverage, measles diseases generally 
showed declining trends. Although, Europe continues 
to fight measles outbreaks [22, 23].
During 2010, a total of 3011 measles cases, including 
confirmed, possible and probable cases, were reported 
in Italy to the enhanced measles surveillance system, 
with a notification rate of 5.0 per 100 000 population. A 
total of 1095 cases were classified as confirmed (36.4%). 
Then, the elimination of indigenous transmission of 
measles by 2015 remains a major challenge for Italy as 
well as for the other European countries. 
To interrupt the circulation of the virus, in addition 
to improving vaccination coverage (≥ 95% with two 
doses of vaccine), public health priorities include 
strengthened surveillance systems and effective 
outbreak control. Laboratory measles surveillance 
is an important tool in measles elimination, since a 
prompt and accurate laboratory diagnosis is essential 
for cases detection, outbreak management and 
ongoing surveillance in countries with low incidence. 
Moreover, the laboratory surveillance for measles and 
rubella, including genetic characterization of wild-
type viruses, permits to illustrate the progress towards 
measles elimination by differentiating viruses between 
indigenous and imported. Major efforts by public 
health will be needed to meet the target of elimination 
by 2015, especially regarding  the laboratory virological 
surveillance.
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